Denali Therapeutics (NASDAQ:DNLI) Share Price Breaks Above 50 Day Moving Average - Should You Sell?

Key Points

• Shares rose 7.8% and moved above the 50-day moving average of $20.35, last trading at $20.96.
• AVLAYAH generated $17.8 million in net product revenue in its second full commercial quarter; Denali expects fourth-quarter revenue of $30 million to $32 million.
• Denali reported $70.1 million in third-quarter net income, but this included a one-time $194 million gain from a voucher sale. The company ended the quarter with $1.0 billion in cash and marketable securities.

Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) shares crossed above its fifty day moving average during trading on Wednesday. The stock has a fifty day moving average of $20.35 and traded as high as $22.19. Denali Therapeutics shares last traded at $20.96, with a volume of 4,900,052 shares traded.

Denali Therapeutics News Summary

Here are the key news stories impacting Denali Therapeutics this week:

• Positive Sentiment: AVLAYAH generated $17.8 million in net product revenue in its second full commercial quarter. Denali expects Q4 revenue of $30 million to $32 million, signaling a sharp sequential increase. Denali Q3 2026 results and business highlights
• Positive Sentiment: Analyst actions were supportive: Morgan Stanley raised its target to $42 and maintained an Overweight rating; Wedbush raised its target to $24 and maintained Outperform; BTIG reaffirmed Buy with a $39 target. These views indicate optimism, though targets are not guarantees. Morgan Stanley research ratings
• Neutral Sentiment: Denali reported $70.1 million in Q3 net income, but that figure included a $194 million one-time gain from the voucher sale. The company ended the quarter with $1.0 billion in cash, cash equivalents and marketable securities. Denali Q3 2026 results and business highlights
• Neutral Sentiment: The company has several potential catalysts ahead, including a planned 2027 BLA submission for zafinofusp and data expected in 2027 from five TransportVehicle programs. These remain development-stage opportunities and carry execution risk. Denali Q3 2026 results and business highlights
• Negative Sentiment: HC Wainwright’s 2027 quarterly forecasts still project losses, ranging from $0.60 per share in Q1 to $0.53 in Q4, underscoring continued costs and the need for sustained product growth. Denali Therapeutics analyst coverage

Analyst Ratings Changes

Several brokerages recently issued reports on DNLI. JPMorgan Chase & Co. began coverage on Denali Therapeutics in a research report on Monday, July 13th. They issued an "overweight" rating and a $29.00 price target on the stock. Wall Street Zen raised Denali Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, October 24th. Deutsche Bank Aktiengesellschaft increased their price objective on Denali Therapeutics from $31.00 to $35.00 and gave the stock a "buy" rating in a research report on Thursday, July 16th. B. Riley Financial boosted their target price on Denali Therapeutics from $30.00 to $35.00 and gave the company a "buy" rating in a report on Tuesday, August 25th. Finally, UBS Group upped their price target on Denali Therapeutics from $25.00 to $34.00 and gave the stock a "buy" rating in a research note on Friday, August 7th. Thirteen investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $36.15.

Denali Therapeutics Trading Up 7.8%

The company has a quick ratio of 8.32, a current ratio of 8.37 and a debt-to-equity ratio of 0.01. The firm has a market cap of $3.35 billion, a price-to-earnings ratio of -12.12 and a beta of 1.08. The business has a 50 day moving average of $20.35 and a 200 day moving average of $21.25.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last posted its quarterly earnings data on Tuesday, November 3rd. The company reported $0.37 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.64. The business had revenue of $17.78 million for the quarter, compared to analyst estimates of $12.67 million. During the same quarter last year, the business earned ($0.74) EPS. On average, research analysts forecast that Denali Therapeutics Inc. will post -2.70 earnings per share for the current fiscal year.

Insider Transactions at Denali Therapeutics

In other news, insider Alexander O. Schuth sold 2,768 shares of the company's stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $23.44, for a total transaction of $64,881.92. Following the completion of the sale, the insider directly owned 278,995 shares in the company, valued at $6,539,642.80. This represents a 0.98% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 9.70% of the company's stock.

Institutional Trading of Denali Therapeutics

Institutional investors have recently modified their holdings of the company. BlackRock Inc. bought a new position in Denali Therapeutics in the second quarter worth about $360,759,000. Dimensional Fund Advisors LP boosted its stake in Denali Therapeutics by 13.4% in the first quarter. Dimensional Fund Advisors LP now owns 2,692,175 shares of the company's stock valued at $51,687,000 after acquiring an additional 317,872 shares during the period. ADAR1 Capital Management LLC boosted its stake in Denali Therapeutics by 3,490.9% in the first quarter. ADAR1 Capital Management LLC now owns 1,871,455 shares of the company's stock valued at $35,932,000 after acquiring an additional 1,819,339 shares during the period. Bank of America Corp DE bought a new position in shares of Denali Therapeutics during the second quarter valued at approximately $31,660,000. Finally, Defilade Capital Management L.P. grew its holdings in shares of Denali Therapeutics by 107.1% during the first quarter. Defilade Capital Management L.P. now owns 1,359,969 shares of the company's stock valued at $26,111,000 after purchasing an additional 703,256 shares during the last quarter. Hedge funds and other institutional investors own 92.92% of the company's stock.

About Denali Therapeutics

Denali Therapeutics Inc is a biopharmaceutical company focused on discovering and developing therapies for patients with neurodegenerative diseases. The company's research programs target conditions including Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, and lysosomal storage disorders.

Denali uses its blood-brain barrier transport technology, known as the Transport Vehicle platform, to design medicines intended to deliver therapeutic proteins and other biologic treatments into the central nervous system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.